OOIR: Observatory of International Research

Papers

(The median citation count of Lancet Infectious Diseases is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Ordinary people in extraordinary times	1944
A step forward in the journey towards hookworm vaccines	1430
Adaora “Ada” Alise Adimora	980
Reflecting on lessons from the 2014–16 Ebola virus outbreak	886
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7	713
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial	621
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis	609
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations	532
Updated criteria for paediatric sepsis and septic shock	480
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial	398
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic	340
Highlights from the sixth ESCMID Conference on Vaccines	317
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges	316
DNDi receives Dutch funding boost	297
HIV vaccine trial failure	283
Research in brief	271
Transitioning to endemicity with COVID-19 research	268
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum	267
Attention to skin-related neglected tropical diseases	260
Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines	254
Research in brief	252
COVID-19 vaccination protects children and adolescents	239
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations	234
A patient with secondary syphilis following incomplete treatment of primary infection	234
Environment and infectious diseases	227

Surge of cutaneous leishmaniasis in Pakistan	217
Infectious disease surveillance update	210
The lasting lessons of mpox: infection, vaccination, and immune memory	208
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review	205
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C	202
Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study	200
Measles immunity gaps and outbreak risk in a shifting landscape	199
Correction to Lancet Infect Dis 2025; 25: e280–93	195
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting	192
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation	190
The superiority of bivalent over monovalent booster vaccines	186
Best practice guidelines for viral hepatitis service delivery in prisons	183
Promoting diversity and equity in publishing	180
Shaping opportunities for future clinical trials in tuberculosis	177
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in wom	177
Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children	177
Kyasanur Forest disease: an emerging arboviral threat	175
Threat of HIV and tuberculosis drug resistance after US funding cuts	173
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1	171
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial	169
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden	167
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study	164
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study	162
Below-knee amputation following osteomyelitis from multidrug-resistant Stenotrophomonas maltophilia in a diabetic foot ulcer	162
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco	160
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect	160
Listeria monocytogenes: a rare, deadly cause of peritonitis	156
The next chapter for Africa's genomic initiatives	155
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria	151
The importance of understanding the infectious microenvironment	149
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial	148
Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blin	147
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis	140
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study	140
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2	138
Mpox in people with past infection or a complete vaccination course: a global case series	138
Research in brief	136
Global cholera resurgence—a preventable tragedy	134
Research in brief	132
New flavours of tuberculosis treatment for children	132
Correction to Lancet Infect Dis 2025; 25: e47–58	131
Patient-centred approaches for drug-resistant tuberculosis	130
Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation	130
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study	129
Curing chronic hepatitis B virus infection	129
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine	127
WHO's first global infection prevention and control report	127
Malaria vaccine development in Mali: a step towards transmission-blocking strategies	126
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant	125
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents	125

Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study	123
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia	123
Post-viral sequelae of COVID-19 and influenza	122
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis	121
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5	120
Addressing the shortage of cholera vaccines	118
Allergic bronchopulmonary aspergillosis with chest pain as atypical symptoms	116
The implications of mpox breakthrough infections on future vaccination strategies	116
A new monoclonal in the arMAMentarium against malaria	114
Theresa Ochoa—staying on top of infectious diseases in Peru	112
Infectious disease surveillance update	111
Research in brief	110
Correction to Lancet Infect Dis 2025; 25: e622	110
Assessment of experimental malaria vaccine induced protection in pre-exposed populations	109
RSV prevention: public health lessons from the southern hemisphere	109
Worrying lack of funding for tuberculosis	107
Full-dose NSAIDs at the first sign of respiratory infection?	106
Severe influenza: is there a role for antiviral combinations?	105
Tuberculosis recovery in Georgia: implementing more by 24	104
Correction to Lancet Infect Dis 2023; 23: e469	104
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa	101
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86	100
Election of Regional Director for the Western Pacific	100
Emil Gotschlich	99
History and evolution of tuberculosis and global health	98
Guidelines adherence as a major protective aspect to increase survival rate in patients with candidaemia in Europe	97
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis	96
Correction to Lancet Infect Dis 2022; published online Aug 31. https://doi.org/10.1016/S1473-3099(22)00434-0	95
Supporting healthcare access for refugees and migrants	95
Is combination antiviral therapy for influenza the optimal approach?	94
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world	94
Interplay of infection and vaccination in long-term protection from COVID-19	94
Serpiginous-like choroiditis in ocular tuberculosis	93
Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention	91
COVID-19 mortality in Africa and Asia – Authors' reply	91
High-dose primaquine reduces vivax relapses: time for change	90
Elisabeth Presterl—always looking forward	89
What can be learnt from the world's first national vaccination programme against gonorrhoea	88
WHO Pathogen X conference	88
We need estimates of gonorrhoea vaccine protection and symptomaticity by sex and anatomical site	88
Research in brief	87
Immune evasiveness of SARS-CoV-2 variants and vaccine selection	85
The response of mpox-associated inflammatory syndrome to steroid therapy	85
WHO publishes update on global antibiotic resistance	85
Vaccine and surveillance implications of dengue underdetection	85
Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study	85
Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products—an update	83
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape	83
Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study	82
Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis	81
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study	80
Twin threats: climate change and zoonoses	80
Effect of change in vaccine schedule on pertussis epidemiology in France: a modelling and serological study	80
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-	80
Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance	79
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial	79
Super-spreaders: a historical review	78
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?	78
The global burden of cryptococcosis—a neglected tropical disease?	77
Infectious disease surveillance update	77
Spreading awareness on lymphatic filariasis	76
COVID-19 mortality in Africa and Asia	76
A step closer to elimination of meningococcal disease	75
Lessons learnt from conducting a randomised clinical trial in eumycetoma	75
RH5.1/Matrix-M: highlighting blood-stage malaria vaccines	74
Statistical concerns for meta-analysis of rare events and small sample sizes – Authors' reply	73
Advancing integration: progress reported for skin NTDs	73
Need for inclusion of high-risk populations and standardisation of immunogenicity outcomes in adult pneumococcal vaccine trials	72
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial	72
Moxidectin versus ivermectin for strongyloidiasis control	71
Pui-Ying Iroh Tam	71
Outbreaks compound Brazil's flooding disaster	71
Social workers and neglected tropical diseases	70
Effectiveness of pyriproxyfen-pyrethroid and chlorfenapyr-pyrethroid long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs for malaria control in the third year post-distribution:	69
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study	69
Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows	69
Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluste	69
Research in brief	69
Correction to Lancet Infect Dis 2023; published online Aug 3. https://doi.org/10.1016/S1473-3099(23)00344-4	68
Incidence and risk factors of tuberculosis among 420 854 household contacts of patients with tuberculosis in the 100 Million Brazilian Cohort (2004–18): a cohort study	68

Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch	68
Unexpected finding in a 17-year-old female undergoing screening colonoscopy	68
Ivermectin for malaria control in mass drug administration programmes	67
Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil	67
Highlights from ECCMID 2022	67
Vaccine pragmatism in the 21st century	67
Next-generation malaria subunit vaccines to reduce disease burden in African children	66
Human ocular thelaziosis—a zoonosis of the eye	66
Is the end of gonorrhoea in sight?	65
Amal Saif Al-Maani—fighting antimicrobial resistance	65
Correction to Lancet Infect Dis 2023; 23: e259–65	65
The urgent need to scale-up fungal diagnostics in Africa	65
On the frontline during the COVID-19 pandemic	64
Sir Michael Anthony Epstein	63
Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices	63
Sleeping sickness: time for dreaming	63
Prevention of non-ventilator-associated hospital-acquired pneumonia in Switzerland: a type 2 hybrid effectiveness–implementation trial	62
Correction to Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00588-7	62
Imprinted hybrid immunity against XBB reinfection	62
The origin of SARS-CoV-2 variants of concern	61
Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa	61
A tale of potential mpox reinfection	61
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial	60
A rare case of rabies-like Australian bat lyssavirus infection	60
Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study	60
Re-emergence of Oropouche virus in Brazil and Latin America	60
Child-friendly rifapentine formulation is a game changer	58
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study	58
Hong Kong's fifth COVID-19 wave—the worst yet	58
DoxyPEP: thinking towards implementation	57
Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings	57
Gender and geographical representation at infectious diseases and clinical microbiology conferences	57
Community-based mpox and sexually transmitted disease surveillance using discarded condoms in the global south	56
doxyPEP: a controversial new tool against STIs	56
Lassa fever research priorities: towards effective medical countermeasures by the end of the decade	56
Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study	56
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis	56
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3	56
National case series of group A streptococcus pleural empyema in children: clinical and microbiological features	56
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster	55
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial	55
The spatiotemporal ecology of Oropouche virus across Latin America: a multidisciplinary, laboratory-based, modelling study	55
Understanding the immunogenicity of RTS,S in infants	55
Alexandra King—promoting Indigenous self-determination	54
Correction to Lancet Infect Dis 2025; 25: e11–12	54
A shared history	54
Sleeper frameworks for Pathogen X: surveillance, risk stratification, and the effectiveness and safety of therapeutic interventions	52
H5N1 avian influenza: tracking outbreaks with real-time epidemiological data	52
A vanquished threat or a cautionary tale?	51
Antiblackness in the Ebola response in Sierra Leone	51
Experts react to SAGO's preliminary report	51
COVID-19 versus influenza: the need to align policies with COVID-19 realities	51
Revisiting oral antivirals for COVID-19 in the hospital setting	51
Deaths of unknown cause in DR Congo	51
A new formulation of praziquantel to achieve schistosomiasis elimination	50
Learning and confirming in publicly funded antiviral trials	50
Successful use of interferon alfa-2a for persistent parvovirus B19 infection	50
Antibiotic stewardship in the real world	49
Developing the EAVE III platform for future health crises	49
Correction to Lancet Infect Dis 2022; published online Jan 25. https://doi.org/10.1016/S1473-3099(21)00586-7	49
A step forward for Plasmodium falciparum malaria transmission-blocking vaccines	49
Randomised controlled trials for mpox in endemic countries	49
Monkeypox trial to begin in DR Congo	49
Correction to Lancet Infect Dis 2023; 23: 789	49
Correction to Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S1473-3099(23)00731-4	48
Lyda Osorio—tackling South America's infectious diseases	48
Lien Jih-ching	48
Correction to Lancet Infect Dis 2025; 25: 764–74	48
Hospital admissions for group A streptococcal infections in England: current rates and historical perspective	48
Candida albicans fungal ball in the eyeball	48
Humanitarian crisis in Tigray amidst civil war	47
Transmissibility of SARS-CoV-2 among fully vaccinated individuals	47
Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prosp	47
Correction to Lancet Infect Dis 2025; published online Oct 29. https://doi.org/10.1016/S1473-3099(25)00466-9	47
Global measles cases up 20% in 2023	47
Salmonella Typhimurium outbreak linked to chocolate	47
Antibody durability at 1 year after Sputnik V vaccination	47
What is the pandemic potential of avian influenza A(H5N1)?	47
Mpox control strategies: using behaviour change to complement, not replace, vaccination	47
Understanding vancomycin nephrotoxicity augmented by β-lactams: a synthesis of endosymbiosis, proximal renal tubule mitochondrial metabolism, and β-lactam chemistry	46
Reporting of deaths during cholera outbreaks: case fatality ratio and community deaths	46
Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia	46
Artificial intelligence to transform public health in Africa	45
Struggling with a new dengue epidemic in Nepal	45
Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and endocarditis	45
Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021–22: a descriptive epidemiological study	45
A new key-player for onchocerciasis elimination	45
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study	44
Azithromycin mass drug administration: balancing survival benefits and risks in children	44
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden	44
The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus	44
Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation	44
Correction to Lancet Infect Dis 2025; published online Feb 13. https://doi.org/10.1016/S1473-3099(24)00749-7	43
Lessons from the English primary care sentinel network's response to the COVID-19 pandemic	43
Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomi	43